DeLLphi-301

一行要約

≥2 prior lines 既治療 ES-SCLC への DLL3×CD3 BiTE Tarlatamab の phase II。ORR 40% (10mg dose), mOS 14.3 mo, mPFS 4.9 mo という SCLC 後治療領域の歴史的成績を達成し、SCLC 治療 paradigm shift を駆動。FDA 2024 accelerated approval、SCLC dirty drug 時代から targeted therapy 時代への転換。

試験デザイン

• 対象: 既治療 ES-SCLC (≥2 prior lines, ECOG ≤1), DLL3 expression 不要、N=222
• Arm A: Tarlatamab 10mg q2w
• Arm B: Tarlatamab 100mg q2w
• Step-up dosing: 1mg → 10mg / 100mg で CRS 緩和

主要結果

• ORR (10mg): 40% (95% CI 29–52%), durability median DoR 9.7 mo
• ORR (100mg): 32% (10mg と同等または若干劣)
• mPFS: 4.9 mo (10mg)
• mOS: 14.3 mo (10mg) — SCLC 後治療として歴史的 (topotecan, lurbinectedin で mOS 7-9 mo)
• AE: CRS (51%, primarily Grade 1-2), ICANS (13%), 倦怠感, 食欲減退

臨床的意義

• SCLC 後治療標準を tarlatamab に変更 (FDA 2024 accelerated approval)
• DLL3 が ASCL1 induced surface marker として確立、ASCL1+ subset の predictive biomarker
• BiTE format の SCLC 適用、HLA-restriction なし → 全 SCLC 患者対応
• 後続: DeLLphi-304 (DLL3 BiTE 維持), DeLLphi-305 (1L maintenance), DeLLphi-303 (LS-SCLC consolidation)

Open Questions

• Tarlatamab 1L maintenance (DeLLphi-305): ES-SCLC 1L IO+chemo 後の維持で OS 改善
• LS-SCLC consolidation (DeLLphi-303 / KEYNOTE-799 echo): chemo放射線後 BiTE consolidation
• CRS / ICANS の outpatient 管理: tocilizumab pre-medication, step-up のさらなる standardization
• Dose optimization: 10mg vs 100mg、より低い用量で同等 efficacy
• Resistance mechanism: antigen escape (DLL3 loss), T cell exhaustion, lineage shift to non-DLL3 subtype

重要論文 Top 10

1. NEJM-2023-Ahn-Tarlatamab for patients with previously treated small-cell lung cancer — DeLLphi-301 primary publication
2. NatMed-2023-Paz-Ares-Tarlatamab a first-in-class DLL3-targeted bispecific T-cell engager in recurrent small cell lung cancer — Phase 1 first-in-human
3. JCO-2024-Paz-Ares-Tarlatamab DLL3 small cell lung cancer DeLLphi-301 — DeLLphi-301 update
4. ★★★★ Rudin et al. NatRevCancer 2019 — SCLC subtype — DLL3 / ASCL1 paradigm
5. CancerCell-2021-Chou-Tarlatamab DLL3 mechanistic basis for SCLC immunotherapy — Tarlatamab 機序基盤

関連エンティティ

• 薬剤クラス: BiTE-bispecific (Tarlatamab DLL3×CD3)
• 遺伝子: ASCL1 (DLL3 induction)
• 関連試験: DeLLphi-303 / 304 / 305
• ドメイン: lung-cancer-treatment / novel-cancer-modalities

関連論文

Clinical-NEC

• Sen et al. LancetOncol 2025 — Pulmonary neuroendocrine neoplasms the molecular landscape, therapeutic challenges, and diagnosis and management

Clinical-SCLC

• Morgensztern et al. ClinCancerRes 2019 — Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing,
• Guan et al. CritRevOncolHematol 2026 — Overcoming immunotherapy resistance in extensive-stage small cell lung cancer insights into mechanisms and therapeutic
• Liu et al. FrontPharmacol 2026 — Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based
• Paulson et al. LancetOncol 2025 — Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after

合成 (Outputs)

• novel-modality-sequencing-driver-resistance
• sclc-molecular-subtype-treatment-selection